sr 48692 has been researched along with Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akunne, HC; Corbin, AE; Demattos, S; Heffner, TG; Pugsley, TA; Whetzel, SZ; Wiley, JN; Wise, LD; Wustrow, DJ | 1 |
| Forgez, P; Gonalons, N; Gully, D; Le Fur, G; Oury-Donat, F; Soubrie, P; Thurneyssen, O | 1 |
2 other study(ies) available for sr 48692 and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.
Topics: Animals; Brain Chemistry; Calcium; Carcinoma; Cells, Cultured; Colonic Neoplasms; Cyclic GMP; Dopamine; Humans; Hypothermia; Locomotion; Male; Membranes; Mice; Neurotensin; Oligopeptides; Psychotropic Drugs; Pyrazoles; Quinolines; Radioligand Assay; Rats | 1995 |
Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non-neuronal cells.
Topics: Animals; Carcinoma; Cell Line; Colon; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Inositol Phosphates; Mice; Neuroblastoma; Neurotensin; Pyrazoles; Quinolines; Receptors, Neurotensin | 1995 |